Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04867785 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3437943 in Participants With Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 281
- Enrollment target
NCT04867785: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT04867785 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 281 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04867785, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 281 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
Primary Outcome
Change in HbA1c (%) from baseline in LY3437943 relative to placebo. HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least squares (LS) mean was calculated using mixed model repeated measures (MMRM) for post-baseline measures: Variable = Treatment\*Time + Strata\*Time + Baseline\*Time.
Interventions
- DRUG Placebo
- DRUG Dulaglutide
- DRUG LY3437943
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 281 participants |
| Start Date | 2021-05-13 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 2 |
What the finished NCT04867785 record still lists
NCT04867785 is an interventional study that assigns participants to a tested intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04867785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04867785 about?
NCT04867785 is a clinical study titled "A Study of LY3437943 in Participants With Type 2 Diabetes". The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.
What is the current status of trial NCT04867785?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 281 participants. The study started on 2021-05-13. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT04867785?
The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG), LY3437943 (DRUG).
Who is sponsoring clinical trial NCT04867785?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04867785's enrollment target sits among peer trials
281 196th of 2000 higher than 1,805 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04521231 · 281 participants · Phase 1
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
- NCT06190730 · 281 participants · NA
REmote Symptom COllection to improVE postopeRative Care
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI